Live Feeds
● TRACKER Updated 13d ago · 43 sources tracked

FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease

The FDA approved rebisufligene etisparvovec, marketed as Fayuvi, providing the first treatment for children with Sanfilippo syndrome type A. This fatal neurodegenerative disorder now has a viable treatment pathway that alters how clinicians handle patient referrals and counseling. To capitalize on the approval, Ultragenyx Pharmaceutical sold a Rare Pediatric Disease Priority Review Voucher for $203 million. This sale, combined with another recent voucher transaction, provided the company with $413 million in non-dilutive funding to purchase additional rare disease assets.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (43)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The FDA approved rebisufligene etisparvovec for the treatment of pediatric Sanfilippo type A.
  • ✓ Ultragenyx Pharmaceutical earned $413 million from the sale of two FDA review vouchers.
  • ✓ Fayuvi is the first approved treatment for Sanfilippo syndrome type A.
🛡️ Source Corroboration: 43 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The generic name rebisufligene etisparvovec was identified as the approved therapy and its impact on clinical referral processes was detailed.

Live updates

  1. FDA approves rebisufligene etisparvovec for Sanfilippo syndrome type A

    The FDA approved rebisufligene etisparvovec, marketed as Fayuvi, providing the first treatment for children with Sanfilippo syndrome type A. This fatal neurodegenerative disorder now has a viable treatment pathway that alters how clinicians handle patient referrals and counseling. To capitalize on the approval, Ultragenyx Pharmaceutical sold a Rare Pediatric Disease Priority Review Voucher for $203 million. This sale, combined with another recent voucher transaction, provided the company with $413 million in non-dilutive funding to purchase additional rare disease assets.

    Why it matters

    Sanfilippo syndrome type A is an ultra-rare disease that causes progressive neurological decline in pediatric patients. The approval of a gene therapy marks a shift from palliative care to active treatment. The associated financial vouchers allow companies to accelerate future drug approvals or sell them to other firms.

    What is confirmed

    • The FDA approved rebisufligene etisparvovec for the treatment of pediatric Sanfilippo type A.
    • Ultragenyx Pharmaceutical earned $413 million from the sale of two FDA review vouchers.
    • Fayuvi is the first approved treatment for Sanfilippo syndrome type A.

    What to watch next

    • Clinical data on long-term efficacy of rebisufligene etisparvovec
    • Ultragenyx announcements regarding new rare disease asset acquisitions
    Sources used for this update (2)
    1. thebrief.health — Sanfilippo Type A Gene Therapy Approval — TheBrief.Health
    2. futurebiotechexpo.com — Ultragenyx Secures $413 Million from FDA Review Voucher Sales ...
    confidence 100%

  2. Ultragenyx Sells Fayuvi Priority Review Voucher for $203 Million

    Ultragenyx Pharmaceutical sold a Rare Pediatric Disease Priority Review Voucher tied to the FDA approval of Fayuvi for $203 million. This transaction was the company's second voucher sale in one week, bringing the total from two gene therapy approvals to $413 million. The non-dilutive funding improves the company's financial position to acquire more rare disease assets. Fayuvi is the first approved treatment for Sanfilippo syndrome type A, a fatal neurodegenerative disorder in children.

    Why it matters

    The FDA approved 13 drugs in September 2026, including first-in-class therapies. This specific approval creates a regulatory precedent for biopharmaceutical companies developing treatments for ultra-rare pediatric conditions.

    What is confirmed

    • Ultragenyx sold a Rare Pediatric Disease Priority Review Voucher tied to Fayuvi for $203 million.
    • The Fayuvi voucher sale was the second priority review voucher Ultragenyx sold in one week.
    • Two priority review voucher sales provided Ultragenyx with $413 million.
    • The FDA approved 13 drugs in September 2026.

    What to watch next

    • Details on the rare disease assets Ultragenyx intends to pursue with the new funding
    • Clinical data on the long-term efficacy of Fayuvi in slowing cognitive decline
    Sources used for this update (7)
    1. www.rttnews.com — FDA Drug Approvals In September 2026
    2. medcitynews.com — Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building - MedCity News
    3. tetmo.com — The Pharma & Biotech Brief — Tuesday, October 13, 2026
    4. finance.yahoo.com — RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a ...
    5. generationhopedoc.substack.com — The first Sanfilippo gene therapy is here — now comes the ...
    6. trial.medpath.com — Ultragenyx Sells Second Rare Pediatric Disease PRV in a Week ...
    7. www.metatrader.com — RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a ...
    confidence 100%

  3. FDA Approves Gene Therapy for Sanfilippo Syndrome

    The FDA has approved Ultragenyx Pharmaceutical's Fayuvi, a gene therapy for pediatric patients with Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA). This is the first approved treatment for the ultra-rare and fatal neurodegenerative disorder. Fayuvi aims to slow cognitive decline in children with this condition.

    Why it matters

    Sanfilippo syndrome is an ultra-rare and fatal neurodegenerative disorder that affects children. The approval of Fayuvi provides a new treatment option for families affected by this condition. The gene therapy was developed by Ultragenyx Pharmaceutical, Inc. and has been shown to slow cognitive decline in children with Sanfilippo syndrome type A.

    What is confirmed

    • The FDA has approved Fayuvi, a gene therapy developed by Ultragenyx Pharmaceutical, Inc. for pediatric patients with Sanfilippo syndrome type A.
    • Fayuvi is the first approved treatment for the ultra-rare and fatal neurodegenerative disorder.
    • Fayuvi aims to slow cognitive decline in children with Sanfilippo syndrome type A.

    What to watch next

    • Availability and accessibility of Fayuvi for patients
    • Further research on the long-term effects of Fayuvi
    • Potential applications of gene therapy for other rare diseases
    Sources used for this update (3)
    1. www.ajmc.com — Rare Disease | Compendium | AJMC
    2. spotlightdelaware.org — ‘All of the joy and grief’: Delaware family perseveres with ...
    3. www.marketscreener.com — Ultragenyx Pharmaceutical Inc.: Official Announcements ...
    confidence 100%

  4. FDA Approves Fayuvi for Sanfilippo Syndrome Type A

    The FDA has approved Fayuvi, a gene therapy developed by Ultragenyx Pharmaceutical, Inc. for pediatric patients with Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA). This is the first approved treatment for the ultra-rare and fatal neurodegenerative disorder. Fayuvi aims to slow cognitive decline in children with this condition.

    Why it matters

    Sanfilippo syndrome type A is a rare and progressive neurodevelopmental disorder with no previous disease-modifying therapeutic options. The approval of Fayuvi provides a new treatment possibility for pediatric patients suffering from this condition. Ultragenyx Pharmaceutical developed Fayuvi as a single-dose AAV9 gene therapy.

    What is confirmed

    • Fayuvi costs $3.95 million.
    • The FDA approval of Fayuvi was based on single-arm evidence and long-term Transpher A data.
    • Fayuvi is a single-dose AAV9 gene therapy developed by Ultragenyx Pharmaceutical, Inc.
    • Sanfilippo syndrome type A is also known as mucopolysaccharidosis type IIIA (MPS IIIA).
    • The FDA issued a priority review voucher to Ultragenyx for FAYUVI.

    What to watch next

    • Ultragenyx Pharmaceutical's European Medicines Agency validation for rebisufligene etisparvovec
    • Further clinical studies on Fayuvi's long-term efficacy
    • FDA's potential future approvals for other Sanfilippo syndrome treatments
    Sources used for this update (8)
    1. www.fda.gov — Food and Drug Administration | FDA
    2. finance.yahoo.com — Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?
    3. www.medscape.com — FDA Neurology Digest: September 2026 - Medscape
    4. www.nature.com — Gene therapy for rare lysosomal storage disorder nabs FDA ...
    5. atebaa.com — FDA Approves Fayuvi as the First Gene Therapy for Pediatric ...
    6. www.healthnewspapers.com — FDA grants Ultragenyx a priority review voucher for its ...
    7. www.mondaq.com — Ultragenyx’s FAYUVI Becomes First FDA-Approved Treatment for ...
    8. www.webmd.com — Fayuvi for Sanfilippo Syndrome Type A: What to Know - WebMD
    confidence 100%

  5. FDA grants full approval to Fayuvi for Sanfilippo syndrome Type A

    The FDA granted full approval to Fayuvi, a single-dose AAV9 gene therapy developed by Ultragenyx for pediatric Sanfilippo syndrome Type A. Approved on September 17, the treatment costs $3.95 million and aims to slow cognitive decline in children with this fatal neurodegenerative disorder. The decision relied on single-arm evidence and long-term Transpher A data. This marks the first approved treatment for the ultra-rare disease, providing Ultragenyx a commercial presence in the MPS IIIA market through its Qualified Treatment Center model and internal manufacturing.

    Why it matters

    Sanfilippo syndrome Type A is a fatal childhood condition that previously had no approved medical interventions. The FDA's approval process for such therapies ensures the safety and efficacy of biological products before they reach the public. This specific gene therapy targets a rare genetic deficiency to halt disease progression.

    What is confirmed

    • The FDA approved Fayuvi on September 17 for pediatric Sanfilippo syndrome Type A.
    • Fayuvi is a single-dose AAV9 gene therapy priced at $3.95 million.
    • The therapy is the first approved treatment for this ultra-rare neurodegenerative disease.
    • Approval was supported by single-arm evidence and long-term Transpher A data.

    What to watch next

    • Real-world data on cognitive decline rates in pediatric patients
    • Implementation results of the Qualified Treatment Center model
    • Utilization rates of the Priority Review Voucher
    Sources used for this update (7)
    1. www.fda.gov — U.S. Food and Drug Administration
    2. www.fda.gov — Drugs | FDA
    3. en.wikipedia.org — Food and Drug Administration - Wikipedia
    4. www.usa.gov — Food and Drug Administration (FDA) | USAGov
    5. www.fda.gov — What We Do | FDA
    6. www.fda.gov — Food | FDA
    7. simplywall.st — Ultragenyx Stock In Focus After First Sanfilippo Type A ...
    confidence 100%

  6. FDA-approved gene therapy slows cognitive decline in Sanfilippo syndrome

    The FDA-approved gene therapy, Fayuvi, from Ultragenyx, has shown promise in halting cognitive decline in pediatric patients with Sanfilippo syndrome Type A. This ultra-rare disease is a fatal childhood disorder with no previously approved treatments. Fayuvi, priced at $3.95 million, was approved on September 17 based on single-arm evidence. Clinical trial data indicates the therapy can slow cognitive decline.

    Why it matters

    Sanfilippo syndrome is a devastating disease with significant unmet medical needs. The approval of Fayuvi marks a major milestone in the treatment of this condition. Ultragenyx's gene therapy aims to address the root cause of the disease, offering new hope for families affected. The FDA's approach to approving treatments for ultra-rare diseases often relies on single-arm trials due to the limited number of patients.

    What is confirmed

    • The FDA approved Ultragenyx's Fayuvi for pediatric patients with Sanfilippo syndrome Type A on September 17.
    • Fayuvi is priced at $3.95 million.
    • The approval was based on single-arm evidence.

    What to watch next

    • Future clinical trial results to confirm long-term efficacy and safety
    • Potential FDA approvals for Sanfilippo syndrome Type B
    • Reimbursement and access decisions for Fayuvi
    Sources used for this update (2)
    1. www.emjreviews.com — Sanfilippo Syndrome Gene Therapy Slows Cognitive Decline
    2. www.biospace.com — Ultragenyx Pharmaceutical Inc. - BioSpace
    confidence 90%

  7. FDA Approves Gene Therapy for Sanfilippo Syndrome

    The FDA approved Ultragenyx's Fayuvi, a gene therapy for pediatric patients with Sanfilippo syndrome Type A, on September 17. This treatment, priced at $3.95 million, is the first approved therapy for this fatal childhood disorder. The approval was based on single-arm evidence, reflecting the agency's approach to ultra-rare diseases.

    Why it matters

    Sanfilippo syndrome is an ultra-rare genetic disorder that causes progressive neurological decline in children. The disease leads to severe cognitive and motor impairments, and there is currently no cure. The approval of Fayuvi offers new hope for families affected by this condition.

    What is confirmed

    • Fayuvi, chemically known as rebisufligene etisparvovec-hopf, is the first FDA-approved treatment for Sanfilippo syndrome Type A.
    • The FDA approval was based on single-arm evidence, reflecting the agency's approach to ultra-rare diseases.
    • Ultragenyx Pharmaceutical priced the therapy at $3.95 million.
    • The gene therapy is authorized for pediatric patients with preserved neurodevelopmental function.
    • Fayuvi uses a modified, non-infectious virus called an adeno-associated virus serotype 9 (AAV9) to deliver a working copy of the SGSH gene into the patient’s cells.

    What to watch next

    • Future studies on the long-term efficacy of Fayuvi
    • Potential approvals for other gene therapies for Sanfilippo syndrome
    • Reactions from advocacy groups and patient communities
    Sources used for this update (16)
    1. www.statnews.com — How a young doctor rose from rural New Mexico to FDA commissioner nominee
    2. www.statnews.com — Heidi Overton, Trump’s pick for FDA head, to face questions at Senate hearing
    3. medcitynews.com — Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder - MedCity News
    4. www.statnews.com — Cancer symptoms can be treated with integrative oncology | STAT
    5. www.statnews.com — Mentally ill women deserve to become parents | STAT
    6. finance.yahoo.com — Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA
    7. www.chroniclelive.co.uk — Gateshead mum's £3m appeal for son, 8, with 'childhood dementia' | Chronicle Live
    8. www.progress.org.uk — FDA approves first gene therapy for Sanfilippo syndrome type ...
    9. sciencemyhealth.com — First Gene Therapy for Pediatric Patients with Sanfilippo ...
    10. curesanfilippofoundation.org — News Room - Cure Sanfilippo Foundation
    11. www.fox6now.com — Children's Wisconsin to offer new gene therapy for Sanfilippo ...
    12. www.bigmoleculewatch.com — Ultragenyx’s FAYUVI Becomes First FDA-Approved Treatment for ...
    confidence 90%

  8. FDA approves first treatment for Sanfilippo syndrome Type A

    The FDA approved Fayuvi on September 17 for pediatric patients with Sanfilippo syndrome Type A who have preserved neurodevelopmental function. This gene therapy, chemically known as rebisufligene etisparvovec-hopf, is the first approved treatment for this fatal childhood disorder. Ultragenyx Pharmaceutical priced the therapy at $3.95 million. The approval followed the FDA's acceptance of single-arm evidence, a move Citeline notes reflects the agency's approach to ultra-rare diseases. Ultragenyx shares rose 13 percent following the news, and the company earned a Priority Review Voucher.

    Why it matters

    Sanfilippo syndrome is a rare neurodegenerative condition that leads to death in children. The use of single-arm evidence for approval suggests a regulatory shift in how the FDA handles diseases with extremely small patient populations.

    What is confirmed

    • The FDA approved Fayuvi on September 17 for pediatric patients with Sanfilippo syndrome Type A.
    • Fayuvi is the first approved treatment for this fatal childhood disorder.
    • Ultragenyx Pharmaceutical priced the therapy at $3.95 million.
    • Ultragenyx shares rose 13 percent after the announcement.
    • The company received a Priority Review Voucher as part of the approval process.

    Still unconfirmed

    • The FDA's approval of Fayuvi indicates a willingness to stretch single-arm evidence in ultra-rare diseases.

    What to watch next

    • Ultragenyx's progress toward its 2027 profitability target
    • Patient outcomes for pediatric users with preserved neurodevelopmental function
    Sources used for this update (4)
    1. finance.yahoo.com — FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
    2. www.statnews.com — Epic’s mortality model, and Omada’s future products
    3. www.statnews.com — HHS unveils new initiatives to reduce animal testing in drug development
    4. insights.citeline.com — Ultragenyx’s Sanfilippo Gene Therapy Nod Illustrates US FDA External Control Expectations
    confidence 100%

  9. FDA Approves Fayuvi as First Gene Therapy for Sanfilippo Syndrome Type A

    The FDA approved Fayuvi, known chemically as rebisufligene etisparvovec-hopf, to treat pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA). Ultragenyx Pharmaceutical priced the treatment at $3.95 million. This represents the first approved therapy for the fatal neurodegenerative condition. Following the announcement, Ultragenyx shares rose 13 percent. The company also received a Priority Review Voucher as part of the approval process.

    Why it matters

    Sanfilippo syndrome Type A is an ultra-rare pediatric disorder that previously lacked any approved market treatments. The approval provides a medical option for a condition that is otherwise fatal.

    What is confirmed

    • Fayuvi is the first gene therapy approved for pediatric patients with mucopolysaccharidosis type IIIA.
    • Ultragenyx Pharmaceutical set the price of the gene therapy at $3.95 million.
    • The FDA approval includes a Priority Review Voucher for Ultragenyx.
    • Ultragenyx stock increased 13 percent following the approval.

    What to watch next

    • Patient access and insurance coverage for the $3.95 million treatment
    • Clinical outcome data from the first group of treated patients
    Sources used for this update (2)
    1. www.statnews.com — Radiopharma companies merge after one receives surprise FDA rejection
    2. www.psychiatryadvisor.com — First Gene Therapy for Sanfilippo Syndrome Type A Gets FDA Approval
    confidence 100%

  10. FDA Approves Fayuvi Gene Therapy for Sanfilippo Syndrome

    The Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy Fayuvi to treat Sanfilippo syndrome Type A, marking the first-ever treatment for the rare neurodegenerative condition. Following the approval, the company set the price for the gene therapy at $3.95 million. Investor reaction drove Ultragenyx stock up 13 percent. The approval also includes a Priority Review Voucher for the company. This marks a major milestone for patients with the fatal pediatric disorder who previously had no approved treatments available on the market.

    Why it matters

    Sanfilippo syndrome is an ultra-rare, fatal neurodegenerative disease that affects pediatric patients. The approval of Fayuvi expands Ultragenyx's commercial gene therapy portfolio and manufacturing footprint in the United States. High-priced gene therapies continue to draw scrutiny as developers set multi-million-dollar price tags for ultra-rare disease treatments.

    What is confirmed

    • The FDA approved Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome.
    • Ultragenyx set a $3.95 million price for the rare disease gene therapy.
    • Ultragenyx stock rose 13 percent following the FDA approval.
    • Fayuvi received full U.S. FDA approval in September 2026 as the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A.

    What to watch next

    • Commercial uptake and patient access to the $3.95 million gene therapy
    • Utilization or sale of the Priority Review Voucher awarded to Ultragenyx
    Sources used for this update (6)
    1. statnews.com — FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
    2. Fierce Pharma — FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorder
    3. Yahoo Finance — RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
    4. Reuters — Ultragenyx sets $3.95 million price for rare disease gene therapy
    5. Endpoints News — Updated: Ultragenyx’s new gene therapy will cost $3.95 million
    6. finance.yahoo.com — How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community